vs
GENMAB A/S（GMAB）与Installed Building Products, Inc.（IBP）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是Installed Building Products, Inc.的1.2倍（$925.0M vs $747.5M），GENMAB A/S净利率更高（36.3% vs 10.2%，领先26.1%），GENMAB A/S同比增速更快（18.7% vs -0.4%），GENMAB A/S自由现金流更多（$327.0M vs $49.3M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Installed Building Products, Inc.是美国领先的建筑产品安装服务商，主营绝缘材料、排水沟、车库门、消防系统及窗帘等产品的专业安装服务，覆盖住宅新建、翻新改造及商业建筑三大领域，业务遍及美国大部分地区。
GMAB vs IBP — 直观对比
营收规模更大
GMAB
是对方的1.2倍
$747.5M
营收增速更快
GMAB
高出19.1%
-0.4%
净利率更高
GMAB
高出26.1%
10.2%
自由现金流更多
GMAB
多$277.7M
$49.3M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $747.5M |
| 净利润 | $336.0M | $76.6M |
| 毛利率 | 93.8% | 35.0% |
| 营业利润率 | 38.9% | 14.6% |
| 净利率 | 36.3% | 10.2% |
| 营收同比 | 18.7% | -0.4% |
| 净利润同比 | 65.5% | 14.5% |
| 每股收益（稀释后） | $5.42 | $2.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABIBP
| Q4 25 | — | $747.5M | ||
| Q3 25 | — | $778.2M | ||
| Q2 25 | $925.0M | $760.3M | ||
| Q1 25 | — | $684.8M | ||
| Q4 24 | — | $750.2M | ||
| Q3 24 | — | $760.6M | ||
| Q2 24 | $779.0M | $737.6M | ||
| Q1 24 | — | $692.9M |
净利润GMABIBP
| Q4 25 | — | $76.6M | ||
| Q3 25 | — | $74.4M | ||
| Q2 25 | $336.0M | $69.0M | ||
| Q1 25 | — | $45.4M | ||
| Q4 24 | — | $66.9M | ||
| Q3 24 | — | $68.6M | ||
| Q2 24 | $203.0M | $65.2M | ||
| Q1 24 | — | $55.9M |
毛利率GMABIBP
| Q4 25 | — | 35.0% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | 93.8% | 34.2% | ||
| Q1 25 | — | 32.7% | ||
| Q4 24 | — | 33.6% | ||
| Q3 24 | — | 33.8% | ||
| Q2 24 | 96.4% | 34.1% | ||
| Q1 24 | — | 33.8% |
营业利润率GMABIBP
| Q4 25 | — | 14.6% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | 38.9% | 13.3% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | 30.3% | 12.9% | ||
| Q1 24 | — | 12.7% |
净利率GMABIBP
| Q4 25 | — | 10.2% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | 36.3% | 9.1% | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | 26.1% | 8.8% | ||
| Q1 24 | — | 8.1% |
每股收益（稀释后）GMABIBP
| Q4 25 | — | $2.81 | ||
| Q3 25 | — | $2.74 | ||
| Q2 25 | $5.42 | $2.52 | ||
| Q1 25 | — | $1.64 | ||
| Q4 24 | — | $2.39 | ||
| Q3 24 | — | $2.44 | ||
| Q2 24 | $3.13 | $2.30 | ||
| Q1 24 | — | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $321.9M |
| 总债务越低越好 | — | $886.6M |
| 股东权益账面价值 | $5.3B | $709.9M |
| 总资产 | $6.5B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 1.25× |
8季度趋势，按日历期对齐
现金及短期投资GMABIBP
| Q4 25 | — | $321.9M | ||
| Q3 25 | — | $333.3M | ||
| Q2 25 | $1.3B | $305.2M | ||
| Q1 25 | — | $298.7M | ||
| Q4 24 | — | $327.6M | ||
| Q3 24 | — | $406.2M | ||
| Q2 24 | $622.0M | $380.3M | ||
| Q1 24 | — | $399.9M |
总债务GMABIBP
| Q4 25 | — | $886.6M | ||
| Q3 25 | — | $880.8M | ||
| Q2 25 | — | $876.1M | ||
| Q1 25 | — | $872.4M | ||
| Q4 24 | — | $874.8M | ||
| Q3 24 | — | $872.3M | ||
| Q2 24 | — | $875.8M | ||
| Q1 24 | — | $875.0M |
股东权益GMABIBP
| Q4 25 | — | $709.9M | ||
| Q3 25 | — | $678.6M | ||
| Q2 25 | $5.3B | $664.5M | ||
| Q1 25 | — | $660.9M | ||
| Q4 24 | — | $705.3M | ||
| Q3 24 | — | $716.4M | ||
| Q2 24 | $4.4B | $685.3M | ||
| Q1 24 | — | $679.2M |
总资产GMABIBP
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $6.5B | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $5.6B | $2.0B | ||
| Q1 24 | — | $2.0B |
负债/权益比GMABIBP
| Q4 25 | — | 1.25× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $64.9M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $49.3M |
| 自由现金流率自由现金流/营收 | 35.4% | 6.6% |
| 资本支出强度资本支出/营收 | 2.4% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.04× | 0.85× |
| 过去12个月自由现金流最近4个季度 | — | $300.8M |
8季度趋势，按日历期对齐
经营现金流GMABIBP
| Q4 25 | — | $64.9M | ||
| Q3 25 | — | $124.0M | ||
| Q2 25 | $349.0M | $90.4M | ||
| Q1 25 | — | $92.1M | ||
| Q4 24 | — | $74.8M | ||
| Q3 24 | — | $101.4M | ||
| Q2 24 | $438.0M | $79.0M | ||
| Q1 24 | — | $84.8M |
自由现金流GMABIBP
| Q4 25 | — | $49.3M | ||
| Q3 25 | — | $104.8M | ||
| Q2 25 | $327.0M | $74.8M | ||
| Q1 25 | — | $71.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $77.3M | ||
| Q2 24 | $430.0M | $58.2M | ||
| Q1 24 | — | $63.0M |
自由现金流率GMABIBP
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 13.5% | ||
| Q2 25 | 35.4% | 9.8% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | 55.2% | 7.9% | ||
| Q1 24 | — | 9.1% |
资本支出强度GMABIBP
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | 2.4% | 2.1% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | 1.0% | 2.8% | ||
| Q1 24 | — | 3.1% |
现金转化率GMABIBP
| Q4 25 | — | 0.85× | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | 1.04× | 1.31× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | 2.16× | 1.21× | ||
| Q1 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
IBP
| Residential New Construction | $488.6M | 65% |
| Other Customer Installation | $67.8M | 9% |
| Shower Doors Shelving And Mirrors | $53.5M | 7% |
| Other Building Products | $47.7M | 6% |
| Fireproofing And Firestopping | $37.6M | 5% |
| Rain Gutters | $31.3M | 4% |
| Window Blinds | $18.0M | 2% |
| Related Party | $6.7M | 1% |
